FDA Continuous Manufacturing Guidance Raises Concerns About Scope and Cost

Executive Summary Makers of brand pharmaceuticals focused on scope issues and the definition of terms in their comments on the US FDA's draft continuous manufacturing guidance, while makers of generic drugs raised concerns about cost and lack of benefit.

Executive Summary

Makers of brand pharmaceuticals focused on scope issues and the definition of terms in their comments on the US FDA's draft continuous manufacturing guidance, while makers of generic drugs raised concerns about cost and lack of benefit.

ContinuousProduction
Source: pink.pharmaintelligence.informa.com